Last Price
36.38
Today's Change
+0.95 (2.68%)
Day's Change
34.79 - 36.70
Trading Volume
603,723
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Kevin Koch Ph.D. Dr. Kevin Koch Ph.D.
Full Time Employees: 97 97
IPO Date: 2021-03-26 2021-03-26
CIK: 0001710072 0001710072
ISIN: US28036F1057 US28036F1057
CUSIP: 28036F105 28036F105
Beta: 0.15 0.15
Last Dividend: 0.00 0.00
Dcf Diff: 35.11 35.11
Dcf: 1.27 1.27
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.